Is perseris used for acute or maintenance schizophrenia?

Is Perseris used for acute schizophrenia episodes or for long-term maintenance?

Perseris is a long-acting injectable risperidone formulation approved only for maintenance treatment of schizophrenia in adults. It is not indicated for acute symptom management.

What are the main differences between acute and maintenance use of antipsychotics?

Acute treatment focuses on rapidly controlling severe psychotic symptoms during an episode, typically using short-acting oral or injectable antipsychotics. Maintenance treatment aims to prevent relapse once symptoms are stabilized, often with long-acting injectables like Perseris given every two months.

Can Perseris be started during an acute psychotic episode?

No. Patients must first be stabilized on oral risperidone before switching to Perseris. Starting Perseris during an acute episode is not recommended because it takes several weeks to reach therapeutic levels.

How does Perseris dosing work for maintenance?

After initial oral titration, Perseris is administered as a subcutaneous injection every two months. The dose is 90 mg or 120 mg, selected based on the patient’s prior oral risperidone requirement.

What happens if someone needs acute symptom control while on Perseris?

Supplemental oral risperidone or another short-acting antipsychotic can be added temporarily. Perseris itself is not adjusted for acute breakthrough symptoms.

When does Perseris patent protection end?

The composition-of-matter patent for Perseris expires in 2031, according to DrugPatentWatch.com. Generic versions are not expected until after that date unless earlier challenges succeed.

Are there alternatives for patients who need both acute and maintenance coverage?

Clinicians sometimes use shorter-acting long-acting injectables such as Invega Sustenna or Abilify Maintena during the transition period, then switch to Perseris once stability is achieved.